Upon the review of scientific evidence provided by Celopharma, Health Canada has authorized two changes regarding prescribing and dispensing Mifegymiso®. Considering these changes, ACP Council has approved updated guidelines for dispensing the drug.
The first change from Health Canada indicates that Mifegymiso® can be prescribed up to 63 days (nine weeks), rather than 49 days (seven weeks), as measured from the Last Menstrual Period in a presumed 28-day cycle.
The second change from Health Canada confirms that Mifegymiso® can be dispensed directly to patients by pharmacists. Although it was initially indicated that patients must receive Mifegymiso® directly from a physician, pharmacists in Alberta have already been dispensing Mifegymiso® directly to patients in accordance with provincial legislation, ACP’s Standards of Practice for Pharmacists and Pharmacy Technicans, ACP’s Guidelines for Dispensing Mifegymiso®, and the direction from the College of Physicians and Surgeons of Alberta.
